Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: lenalidomide, thalidomide, pomalidomide +1 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 1,033 | 0.71 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6429
Sealed predictions
- CRBN in dopamine neurons, braak+0.35 (p 0.361) → +0.34 (p 0.373)receipt 6436
Swarm cases
receipt 6436: CRBN in dopamine neurons, braak
- power
- full sample +0.31 (p 0.214, n 18), 95% CI -0.19 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.30 (p 0.225, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.273, n 18). could be the mix.
- skeptic
- leave-one-out range +0.22 to +0.43, sign flips 0; without severely affected donors +0.31 (p 0.214, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CRBN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts